saquinavir + stavudine + lamivudine

A combination antiretroviral regimen composed of **saquinavir**, **stavudine**, and **lamivudine**. - **Saquinavir** is a selective HIV-1 protease inhibitor, impeding viral replication by preventing the cleavage of viral polyproteins, thus inhibiting the maturation of infectious virions[3]. - **Stavudine** is a synthetic thymidine nucleoside analogue and acts as a nucleoside reverse transcriptase inhibitor (NRTI), terminating HIV DNA chain elongation when incorporated into the viral genome[1]. - **Lamivudine** is a cytidine nucleoside analogue (NRTI) that inhibits both HIV-1 reverse transcriptase and hepatitis B virus polymerase through chain termination, suppressing replication in HIV and HBV[1]. These three drugs are used in combination for the **treatment of HIV-1 infection**; there is no evidence this exact triple combination is marketed as a fixed-dose single product, but its components are approved for antiretroviral therapy regimens.